WO1994023070A1 - RECOMBINANT α-N-ACETYLGALACTOSAMINIDASE ENZYME AND cDNA ENCODING SAID ENZYME - Google Patents

RECOMBINANT α-N-ACETYLGALACTOSAMINIDASE ENZYME AND cDNA ENCODING SAID ENZYME Download PDF

Info

Publication number
WO1994023070A1
WO1994023070A1 PCT/US1994/003338 US9403338W WO9423070A1 WO 1994023070 A1 WO1994023070 A1 WO 1994023070A1 US 9403338 W US9403338 W US 9403338W WO 9423070 A1 WO9423070 A1 WO 9423070A1
Authority
WO
WIPO (PCT)
Prior art keywords
acetylgalactosaminidase
enzyme
chicken liver
recombinant
amino acid
Prior art date
Application number
PCT/US1994/003338
Other languages
French (fr)
Inventor
Alex Zhu
Jack Goldstein
Original Assignee
New York Blood Center, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York Blood Center, Inc. filed Critical New York Blood Center, Inc.
Priority to JP6522254A priority Critical patent/JPH08508406A/en
Priority to AU64175/94A priority patent/AU688310B2/en
Priority to EP94911730A priority patent/EP0694081A4/en
Priority to CA002159083A priority patent/CA2159083C/en
Publication of WO1994023070A1 publication Critical patent/WO1994023070A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01049—Alpha-N-acetylgalactosaminidase (3.2.1.49)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)

Definitions

  • This invention relates to a recombinant enzyme for use in the removal of type A antigens from the surface of cells in blood products, thereby converting certain sub-type A blood products to type 0 blood products and certain type AB blood products to type B blood products.
  • This invention further relates to methods of cloning and expressing said recombinant enzyme.
  • this invention is directed to a recombinant chicken liver ⁇ -N-acetylgalactosaminidase enzyme, methods of cloning and expressing said recombinant ⁇ -N-acetylgalactosaminidase enzyme, and a method of removing type A antigens from the surface of cells in type A and AB blood products using said recombinant ⁇ -N-acetylgalactosaminidase enzyme by contacting said enzyme with blood products so as to remove the terminal moiety of the A-antigenic determinant from the surface of cells (for example, erythrocytes) in said blood products, while allowing the structure and function of the cells in the blood products to remain intact.
  • a recombinant chicken liver ⁇ -N-acetylgalactosaminidase enzyme methods of cloning and expressing said recombinant ⁇ -N-acetylgalactosaminidase enzyme, and a method of removing type A anti
  • the recombinant ⁇ -N-acetylgalactosaminidase enzyme of this invention provides a readily available and cost-efficient enzyme which can be used in the removal of type A antigens from the surface of cells in type A and AB blood products.
  • Treatment of certain sub-type A blood products with the recombinant enzyme of this invention provides a source of cells free of the A antigen, which blood products are thereby rendered useful in transfusion therapy in the same manner of 0 type blood products.
  • blood products includes whole blood and cellular components derived from blood, including erythrocytes (red blood cells) and platelets.
  • blood group or type systems, one of the most important of which is the ABO system.
  • This system is based on the presence or absence of antigens A and/or B. These antigens are found on the surface of erythrocytes and on the surface of all endothelial and most epithelial cells as well.
  • the major blood product used for transfusion is erythrocytes, which are red blood cells containing hemoglobin, the principal function of which is the transport of oxygen.
  • Blood of group A contains antigen A on its erythrocytes.
  • blood of group B contains antigen B on its erythrocytes.
  • Blood of group AB contains both antigens
  • blood of group 0 contains neither antigen.
  • the blood group structures are glycoproteins or glycolipids and considerable work has been done to identify the specific structures making up the A and B determinants or antigens. It has been found that the blood group specificity is determined by the nature and linkage of monosaccharides at the ends of the carbohydrate chains.
  • the carbohydrate chains are attached to a peptide or lipid backbone which is embedded in the lipid bi-layer of the membrane of the cells.
  • the most important (immuno-dominant or immuno-determinant) sugar has been found to be N-acetylgalactosamine for the type A antigen and galactose for the type B antigen.
  • a 1 erythrocytes have more antigenic A sites, i.e., terminal N-acetylgalactosamine residues, than A int erythrocytes which in turn have more antigenic A sites than A 2 erythrocytes.
  • a transferase enzymes responsible for the formation of A antigens differ biochemically from each other in A 1 , A in t and A 2 individuals. Some A antigens found in A 1 cells contain dual A antigenic sites.
  • Blood of group A contains antibodies to antigen B. Conversely, blood of group B contains antibodies to antigen A. Blood of group AB has neither antibody, and blood group O has both. A person whose blood contains either (or both) of the anti-A or anti-B antibodies cannot receive a transfusion of blood containing the corresponding incompatible antigen(s). If a person receives a transfusion of blood of an incompatible group, the blood transfusion recipient's antibodies coat the red blood cells of the transfused incompatible group and cause the transfused red blood cells to agglutinate, or stick together. Transfusion reactions and/or hemolysis (the destruction of red blood cells) may result therefrom.
  • transfusion blood type is cross-matched against the blood type of the transfusion recipient.
  • a blood type A recipient can be safely transfused with type A blood which contains compatible antigens.
  • type 0 blood contains no A or B antigens, it can be transfused into any recipient with any blood type, i.e., recipients with blood types A, B, AB or 0.
  • type O blood is considered "universal", and may be used for all transfusions.
  • the process for converting A int and A 2 erythrocytes to erythrocytes of the H antigen type which is described in the '627 Patent includes the steps of equilibrating certain sub-type A or AB erythrocytes, contacting the equilibrated erythrocytes with purified chicken liver ⁇ -N-acetylgalactosaminidase enzyme for a period sufficient to convert the A antigen to the H antigen, removing the enzyme from the erythrocytes and re-equilibrating the erythrocytes.
  • ⁇ -N-acetylgalactosaminidase obtained from an avian liver (specifically, chicken liver) source was found to have superior activity in respect of enzymatic conversion or cleavage of A antigenic sites.
  • ⁇ -N-acetylgalactosaminidase enzymes are characterized (and thereby named) by their ability to cleave N-acetylgalactosamine sugar groups. In isolating or identifying these enzymes, their activity is assessed in the laboratory by evaluating cleavage of synthetic substrates which mimic the sugar groups cleaved by the enzymes, with p-nitrophenylglycopyranoside derivatives of the target sugar groups being commonly used.
  • these synthetic substrates are simple structurally and small-sized and mimic only a portion of the natural glycoproteins and glycolipid structures which are of primary concern, those being the A antigens on the surface of cells.
  • a natural glycolipid substrate originally isolated from sheep erythrocytes, is the Forsmann antigen (globopentaglycosylceramide).
  • the Forsmann antigen substrate appropriately mimics the natural A antigen glycolipid structures and is therefore utilized to predict the activity of ⁇ -N-acetylgalactosaminidase enzymes against the A antigen substrate. Isolated Forsmann antigen glycolipids have been shown to inhibit hemolysis of sheep red cells by immune rabbit anti-A serum in the presence of serum complement.
  • ⁇ -N-acetylgalactosaminindase enzyme has been isolated from a number of sources besides chicken liver (described above), including bacteria, mollusks, earthworms, and human liver.
  • the human ⁇ -N-acetylgalactosaminidase enzyme has been purified, sequenced, cloned and expressed. For example, in "Human ⁇ -N-Acetylgalactosaminidase - Molecular Cloning, Nucleotide Sequence and Expression of a Full-length cDNA", by Wang et al., in The Journal of Biological Chemistry, Vol. 265, No.
  • the velocity of an enzyme cleavage reaction is measured in the Vmax, the reaction rate at a saturating concentration of substrate. A higher Vmax indicates a faster cleavage rate.
  • the ratio of these two parameters, Vmax/Km is a measure of the overall efficiency of an enzyme in reacting with (cleaving) a given substrate. A higher Vmax/Km indicates greater enzyme efficiency.
  • the enzyme For successful and clinically applicable removal of A antigens from the surface of cells, the enzyme must be sufficiently active at or above a pH at which the cells being treated can be maintained. The procedure described in the '627 patent calls for treatment of cells at or above a pH of 5.6. Therefore, the pH optimum of an appropriate enzyme must still provide reasonable enzyme activity at this pH.
  • Vmax/Km, Vmax, Km and pH optimum are reported for the human ⁇ -N-acetylgalactosaminidase enzyme in "Studies on Human Liver ⁇ -galactosidases", by Dean et al. in The Journal of Biological Chemistry, Vol. 254, No. 20, pages 10001-10005 (1979).
  • the Vmax/Km value for the Forsmann antigen of human ⁇ -N-acetylgalactosaminidase is 0.46, as compared to a Vmax/Km value of 5.0 for the chicken liver enzyme, indicating an approximately ten-fold difference in efficiency.
  • the Km is lower and the Vmax is higher for the chicken liver enzyme, compared to the human enzyme.
  • human ⁇ -N-acetylgalactosaminidase has a pH optimum for the Forsmann antigen of 3.9, compared to 4.7 for chicken liver ⁇ -N-acetylgalactosaminida ⁇ e. By all of these enzyme characteristics, human ⁇ -N-acetylgalactosaminidase enzyme is not suitable for removal of A antigens, particularly when compared to the chicken liver enzyme.
  • Figure 1 represents a diagram of the strategy used to clone and sequence the chicken liver ⁇ -N-acetylgalactosaminidase cDNA
  • Figure 2 represents the nucleic acid sequence and the deduced amino acid sequence of the chicken liver ⁇ -N-acetylgalactosaminidase cDNA clone;
  • Figure 3 represents the expression of chicken liver ⁇ -N-acetylgalactosaminidase in bacteria and rabbit reticulocyte lysate as shown by Western blot;
  • Figure 4 represents a homology comparison between ⁇ -N-acetylgalactosaminidases and ⁇ -galactosidases;
  • Figure 5 represents the expression of chicken liver ⁇ -N-acetylgalactosaminidase in yeast as shown by Western blot.
  • This invention is directed to a recombinant chicken liver ⁇ -N-acetylgalactosaminidase enzyme, which enzyme has a molecular weight of about 45 kDa, is immunoreactive with an antibody specific for chicken liver ⁇ -N-acetylgalactosaminidase, and also has about 80% amino acid sequence homology with human ⁇ -N-acetylgalactosaminidase enzyme.
  • the recombinant chicken liver ⁇ -N-acetylgalactosaminidase enzyme of this invention has the amino acid sequence depicted in Figure 2, from amino acid number 1 to amino acid number 406.
  • This invention is further directed to methods of cloning and expressing the recombinant chicken liver ⁇ -N-acetylgalactosaminidase enzyme, and to a method of using said enzyme to remove A antigens from the surface of cells in blood products so as to convert said blood products of certain A sub-types to type O, thereby rendering said blood products universal for use in transfusion therapy.
  • This invention is directed to a recombinant enzyme for use in the removal of type A antigens from the surface of cells in blood products, thereby converting certain sub-type A blood products to type 0 blood products and certain sub-type AB blood products to type B blood products.
  • the recombinant chicken liver ⁇ -N-acetylgalactosaminidase enzyme of this invention has a molecular weight of about 45 kDa and is immunoreactive with an antibody specific for chicken liver ⁇ -N- acetylgalactosaminidase.
  • the recombinant enzyme of this invention has about 80% amino acid sequence homology with human ⁇ -N-acetylgalactosaminidase enzyme.
  • the recombinant chicken liver ⁇ -N-acetylgalactosaminidase enzyme of this invention has the following nucleic acid and deduced amino acid sequence:
  • a DNA vector containing a sequence encoding chicken liver ⁇ -N-acetylgalactosaminidase was deposited under the
  • the recombinant chicken liver ⁇ -N- acetylgalactosaminidase enzyme of this invention can be cloned and expressed so that it is readily available for use in the removal of A antigens from the surface of cells in blood products.
  • the enzyme of this invention can be cloned and expressed by screening a chicken liver cDNA library to obtain the cDNA sequence which encodes the chicken liver ⁇ -N-acetylgalactosaminidase, sequencing the encoding cDNA once it is determined, cloning the encoding cDNA and expressing ⁇ -N-acetylgalactosaminidase from the cloned encoding cDNA.
  • This may be performed by obtaining an amplified human ⁇ -N-acetylgalactosaminidase fragment capable of use as a screening probe, screening a chicken liver cDNA library, such as the one described hereinabove, using the amplified human ⁇ -N-acetylgalactosaminidase fragment as a probe so as to obtain the cDNA sequence of the chicken liver cDNA library which encodes chicken liver ⁇ -N-acetylgalactosaminidase, sequencing the encoding DNA, cloning the encoding DNA and expressing chicken liver ⁇ -N-acetylgalactosaminidase enzyme from the cloned encoding cDNA.
  • screening can be performed using antibodies which recognize chicken liver ⁇ -N-acetylgalactosaminidase.
  • expression vectors containing the chicken liver ⁇ -N-acetylgalactosaminidase coding sequence can be used to construct expression vectors containing the chicken liver ⁇ -N-acetylgalactosaminidase coding sequence, with appropriate transcriptional/translational signals for expression of the enzyme in the corresponding expression systems.
  • Appropriate organisms, cell types and expression systems include: cell-free systems such as a rabbit reticulocyte lysate system, prokaryotic bacteria, such as E. coli, eukaryotic cells, such as yeast, insect cells, mammalian cells (including human hepatocytes or Chinese hamster ovary (CHO) cells), plant cells or systems, and animal systems including oocytes and transgenic animals.
  • the entire chicken liver ⁇ -N-acetylgalactosaminidase coding sequence or functional fragments of functional equivalents thereof may be used to construct the above expression vectors for production of functionally active enzyme in the corresponding expression system. Due to the degeneracy of the DNA code, it is anticipated that other DNA sequences which encode substantially the same amino acid sequence may be used. Additionally, changes to the DNA coding sequence which alter the amino acid sequence of the chicken liver ⁇ -N-acetylgalactosaminidase enzyme may be introduced which result in the expression of functionally active enzyme. In particular, amino acid substitutions may be introduced which are based on similarity to the replaced amino acids, particularly with regard to the charge, polarity, hydrophobicity, hydrophilicity, and size of the side chains of the amino acids.
  • Sub-type A antigens can be removed from the surface of erythrocytes by contacting the erythrocytes with the recombinant chicken liver ⁇ -N-acetylgalactosaminidase enzyme of this invention for a period of time sufficient to remove the A antigens from the surface of the erythrocytes.
  • Chicken liver ⁇ -N-acetylgalactosaminidase was purified to homogeneity.
  • the enzyme was a glycoprotein with a molecular weight of 80 kDa, and was dissociated into two identical subunits at pH 7.5. Its optimal pH for cleavage of the synthetic p-nitrophenyl- ⁇ -N-acetylgalactosaminyl- pyranoside substrate was 3.65 and the activity dropped sharply when the pH was raised above 7.
  • N-terminal sequence obtained from the purified chicken liver ⁇ -N-acetylgalactosaminidase showed a strong homology with the corresponding sequence deduced from the human ⁇ -N-acetylgalactosaminidase cDNA clone described in Tsuj i et al., and Wang et al.
  • a DNA fragment corresponding to human ⁇ -N-acetylgalactosaminidase residues from 688 to 1236 was amplified from the cDNA by the hot-start PCR technique.
  • the PCR reaction mixture was preheated at 95°C for 5 minutes and maintained at 80°C while Taq DNA polymerase (Promega) was added to reduce the possible non-specific annealing at lower temperature. 35 cycles of amplification was then carried out as follows: 94°C for 1 minute, 50°C for 2 minutes and 72°C for 3 minutes. The same conditions for PCR were applied in all of the following experiments.
  • the PCR-amplified fragment was then used as a radioactively-labeled probe in the screening of a chicken liver cDNA library (Stratagene) based on homology hybridization.
  • the filters containing the library were hybridized with the probe overnight at 42°C in a solution of 50% formamide, 5XSSPE, 5XDenhardt ' s, 0.1% SDS and 0.1 mg/ml salmon sperm DNA. The filters were then washed as follows:
  • the filters were autoradiographed overnight at -70°C.
  • the positive clones were picked up for the second-round screening following the same procedure. In total, three consecutive screenings were carried out in order to obtain a well-isolated positive clone.
  • the library was rescreened by using the 1.9 kb cDNA clone as a probe. However, no positive clone was identified by this approach.
  • the upstream cDNA sequence was then obtained by applying multiple amplification (the nested PCR technique) of. a second chicken liver cDNA library (Clontech).
  • Figure 1 represents a diagram of the strategy used to clone and sequence the chicken liver ⁇ -N-acetylgalactosaminidase cDNA.
  • the cDNA encoding chicken liver ⁇ -N-acetylgalactosaminidase contained a 1.2 kb coding region (slashed area) and a 1.2 kb 3' untranslated region.
  • the arrows at the bottom of the diagram indicate the sequencing strategy.
  • CL1, CL2 and CL3 are oligonucleotides used as primers for the nested PCR.
  • CL1 and CL2 are located at position 924-941 nt and 736-753 nt, respectively (see Figure 2).
  • the oligonucleotide CL3 [5'-CTGGAGAAC(T)GGA(GC)CTGGCT(CA)CG] was designed taking into account chicken codon usage and "best guess".
  • the whole cDNA library was used as a template in the presence of one specific primer (CL1) (see Figure 1) and one universal primer derived from the library vector (5'-CTGGTAATGGTAGCGACC) .
  • CL1 specific primer
  • CL3 universal primer derived from the library vector
  • a small aliquot from the above reaction was directly taken for the second-round amplification with a different set of primers.
  • the primer CL2 had the sequence located upstream of CL1 ( Figure 1) and the second primer, CL3, was designed based on the N-terminal amino acid sequence from purified chicken liver ⁇ -N-acetylgalactosaminidase (see Figure 1).
  • a 750 bp fragment was sequenced to eliminate any possible PCR artifacts.
  • Figure 2 represents the nucleic acid sequence and deduced amino acid sequence of the chicken liver ⁇ -N-acetylgalactosaminidase cDNA clone.
  • the underlined regions in Figure 2 match sequences obtained from the N-terminus and CNBr-derived fragments of enzyme purified from chicken liver.
  • the first 3 nucleotides, ATG, were added during subcloning to serve as the translational initiation codon for protein expression.
  • the polyadenylation signal (AATAAA) at positions 2299-2304 nt is double-underlined.
  • the boxed sequence indicates potential sites for N-glycosylation.
  • the mature protein of 405 amino acids has a molecular mass of about 45 kDa, consistent with that of the purified enzyme estimated by SDS-PAGE. Due to the cloning approach applied, the sequence at the 5' end of the cDNA corresponded to the N-terminal sequence of the mature enzyme isolated from chicken liver.
  • the sequence from 1 to 1260 nucleotides which contained the coding region for chicken liver ⁇ -N-acetylgalactosaminidase was subcloned into the vector PCR-II (Invitrogen) in such an orientation that the T7 promoter was located upstream of the insert. Since the N-terminus of the mature protein started with leucine, a translational initiation codon, ATG, was added during the subcloning construction. The construct was then used as a template in a transcription-translation coupled system, TNT system (Promega), for protein expression according to the procedure recommended by the manufacturer.
  • TNT system Promega
  • the cDNA was subcloned into the EcoRI site of the pTrcHis vector (Invitrogen) for expression in E. coli. Because of the sequence in the vector, the expressed enzyme contained a polyhistidine-tag in its N-terminus, which permitted one step purification by affinity chromatography from crude cell lysates.
  • Figure 3 represents the expression of chicken liver ⁇ -N-acetylgalactosaminidase in bacteria and rabbit reticulocyte lysate as shown by Western blotting.
  • Lane 1 through lane 4 demonstrate the results of expression in a rabbit reticulocyte lysate.
  • the expression was carried out in lysate in the presence of 35 S-methiomne with (lane 1) or without (lane 2) the expression plasmid.
  • 5 ⁇ l of the reaction sample was loaded to a 12% SDS-PAGE.
  • the gel was dried and autoradiographed for 2 hours and a band of an apparent molecular weight of about 45KDa was visualized with the expression plasmid (lane 1, Figure 3).
  • a Western blot was performed using a polyclonal antibody raised against ⁇ -N-acetylgalactosaminidase purified from chicken liver.
  • the chicken liver ⁇ -N-acetylgalactosaminidase sequence was compared with published sequences of other ⁇ -N-acetylgalactosaminidases and ⁇ -galactosidases which cleave ⁇ -galactose sugar groups.
  • Figure 4 shows a homology comparison between various ⁇ -N-acetylgalactosaminidases and ⁇ -galactosidases. Alignment was carried out using both the computer program PROSIS (Hitachi Software Engineering Corp., Ltd.) and manual arrangement. The amino acid sequences were deduced from cDNAs.
  • Sequences I and II are of ⁇ -N-acetylgalactosaminidases from chicken liver and human placenta, respectively.
  • Sequences III, IV, V and VI represent ⁇ -galactosidase from human, yeast, Cyamopsis tetragonoloba and Aspergillus niger, respectively.
  • Sequences IV and VI are truncated at the C-terminus, as indicated by **. Identical or conservatively substituted amino acid residues (five out of six or more) among the aligned protein sequences are boxed. The numbers above the sequences indicate the relative position of each peptide sequence.
  • the deduced amino acid sequence from chicken liver ⁇ -N-acetylgalactosaminidase cDNA shows approximately 80% homology with the human ⁇ -N-acetylgalactosaminidase as determined by PROSIS. This homology indicates the relatedness of the human and chicken liver enzymes, despite the differences in the specific characteristics of the enzymes, particularly with regard to cleavage of the Forsmann antigen, as has already been described. Also, polyclonal antibodies raised against chicken liver ⁇ -N-acetylgalactosaminidase enzyme do not cross react with the human enzyme. The specific amino acids responsible for these differences remain to be elucidated.
  • Yamachi et al. (1990) reported that a human ⁇ -N-acetylgalactosaminidase cDNA with an insertion of 70bp at the position corresponding to number 376 in Figure 4 was not enzymatically active in a transient expression study in COS cells.
  • the data suggests that the open reading frame shift caused by this insertion in the C-terminal portion of the molecule is responsible for the loss of enzymatic activity, indicating that amino acids in the C-terminal region may be essential for ⁇ -N-acetylgalactosaminidase enzyme activity.
  • the first 48 nucleotides of human ⁇ -N-acetylgalactosaminidase cDNA (Wang, et al. 1990) which correspond to the signal peptide sequence, were linked to the cloned chicken liver ⁇ -N-acetylgalactosaminidase coding region by PCR.
  • the PCR amplified product was subcloned directly into the vector PCR-II (Invitrogen).
  • Two EcoRl sites flanking the insert were used to subclone the entire ⁇ -N-acetylgalactosaminidase cDNA into the yeast expression vector pYES2 (Invitrogen) in such an orientation that the GAL 1 promoter was located upstream of the insert.
  • the GAL 1 promoter provides expression of the inserted cDNA clone under galactose inducing growth conditions in yeast.
  • the yeast vector constructs were transformed into the yeast strain, INVSCI (Invitrogen) using standard procedures.
  • INVSCI Invitrogen
  • the total proteins from cell extract and culture supernatant were prepared and separated by 12% SDS-PAGE and a Western blot performed (by standard conditions) using the polyclonal antibody raised against purified chicken liver ⁇ -N-acetylgalactosaminidase.
  • the transformed yeast cells were grown in medium without uracil (Bio 101, Inc.). After 0.2% galactose induction, the cells were centrifuged and protein extracts were prepared using glass bead disruption. The secreted proteins in the culture supernatant were concentrated with a Centricon-30 (Amicon Division, W.R. Grace & Co.). The Western blot results are depicted in Figure 5.
  • Lanes 1 and 8 of Figure 5 show the ⁇ -N-acetylgalactosaminidase purified from chicken liver.
  • Lane 2 through lane 4 are cell extracts from the yeast transformed with three different pYES2 constructs: the vector alone (lane 2), chicken liver ⁇ -N-acetylgalactosaminidase cDNA coding region (lane 3), and the coding region plus signal sequence (lane 4).
  • Lane 5 is the culture supernatant from transformed yeast used in Lane 4.
  • Lane 7 shows the molecular weight standard. As shown in Figure 5, while the protein without signal peptide was expressed within yeast cells (lane 3), the protein with a signal peptide sequence was predominantly secreted into the media (lane 5). The larger molecular weight of the secreted protein observed on the Western blot was presumably caused by overglycosylation, as was observed for the expression of guar ⁇ -galactosidase in yeast (Fellinger, et al. 1991).
  • the expressed enzyme eluted from the column demonstrates activity toward the synthetic substrate p-nitrophenyl- ⁇ -N-acetylgalactosaminylpyranoside at pH 3.6. Heavily glycosylated enzyme did not bind to the affinity column and showed no activity against synthetic substrate. All the data taken together demonstrate production, secretion and purification of enzymatically active chicken liver ⁇ -N-acetylgalactosaminidase in yeast cells.
  • NAME/KEY chicken liver ⁇ -N- acetylgalactosaminidase
  • NAME/KEY chicken liver ⁇ -N- acetylgalactosaminidase
  • ORGANISM yeast Saccharomyces cerevisiae
  • NAME/KEY yeast ⁇ -galactosidase (MEL1)
  • ORGANISM guar plant Cyamopsis tetragonoloba
  • ORGANISM Aspergillis niger

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

This invention relates to a recombinant enzyme for use in the removal of A antigens from the surface of cells in blood products. Specifically, this invention is directed to a recombinant α-N-acetylgalactosaminidase enzyme from chicken liver, methods of cloning and expressing said recombinant α-N-acetylgalactosaminidase enzyme and a method of removing A antigens from the surface of cells in blood products using said recombinant α-N-acetylgalactosaminidase enzyme.

Description

RECOMBINANT α-N-ACETYLGALACTOSAMINIDASE
ENZYME AND cDNA ENCODING SAID ENZYME
Statement of Government Interest
This invention was made with government support under NMRDC Grant Number N0014-90-J-1638. As such, the government has certain rights in the invention.
CROSS REFERENCE TO RELATED APPLICATIONS
This Application is a Continuation-In-Part of Application Serial No. 07/964,756 filed October 22, 1992, entitled PREPARATION OF ENZYME FOR CONVERSION OF SUB-TYPE A AND AB ERYTHROCYTES .
FIELD OF THE INVENTION
This invention relates to a recombinant enzyme for use in the removal of type A antigens from the surface of cells in blood products, thereby converting certain sub-type A blood products to type 0 blood products and certain type AB blood products to type B blood products. This invention further relates to methods of cloning and expressing said recombinant enzyme. More particularly, this invention is directed to a recombinant chicken liver α-N-acetylgalactosaminidase enzyme, methods of cloning and expressing said recombinant α-N-acetylgalactosaminidase enzyme, and a method of removing type A antigens from the surface of cells in type A and AB blood products using said recombinant α-N-acetylgalactosaminidase enzyme by contacting said enzyme with blood products so as to remove the terminal moiety of the A-antigenic determinant from the surface of cells (for example, erythrocytes) in said blood products, while allowing the structure and function of the cells in the blood products to remain intact. The recombinant α-N-acetylgalactosaminidase enzyme of this invention provides a readily available and cost-efficient enzyme which can be used in the removal of type A antigens from the surface of cells in type A and AB blood products. Treatment of certain sub-type A blood products with the recombinant enzyme of this invention provides a source of cells free of the A antigen, which blood products are thereby rendered useful in transfusion therapy in the same manner of 0 type blood products.
BACKGROUND OF THE INVENTION
As used herein, the term "blood products" includes whole blood and cellular components derived from blood, including erythrocytes (red blood cells) and platelets.
There are more than thirty blood group (or type) systems, one of the most important of which is the ABO system. This system is based on the presence or absence of antigens A and/or B. These antigens are found on the surface of erythrocytes and on the surface of all endothelial and most epithelial cells as well. The major blood product used for transfusion is erythrocytes, which are red blood cells containing hemoglobin, the principal function of which is the transport of oxygen. Blood of group A contains antigen A on its erythrocytes. Similarly, blood of group B contains antigen B on its erythrocytes. Blood of group AB contains both antigens, and blood of group 0 contains neither antigen.
The blood group structures are glycoproteins or glycolipids and considerable work has been done to identify the specific structures making up the A and B determinants or antigens. It has been found that the blood group specificity is determined by the nature and linkage of monosaccharides at the ends of the carbohydrate chains. The carbohydrate chains are attached to a peptide or lipid backbone which is embedded in the lipid bi-layer of the membrane of the cells. The most important (immuno-dominant or immuno-determinant) sugar has been found to be N-acetylgalactosamine for the type A antigen and galactose for the type B antigen.
There are three recognized major sub-types of blood type A. These sub-types are known as A1, A intermediate (Ai nt) and A2. There are both quantitative and qualitative differences which distinguish these three sub-types. Quantitatively, A1 erythrocytes have more antigenic A sites, i.e., terminal N-acetylgalactosamine residues, than Aint erythrocytes which in turn have more antigenic A sites than A2 erythrocytes. Qualitatively, the transferase enzymes responsible for the formation of A antigens differ biochemically from each other in A1, Ain t and A2 individuals. Some A antigens found in A1 cells contain dual A antigenic sites.
Blood of group A contains antibodies to antigen B. Conversely, blood of group B contains antibodies to antigen A. Blood of group AB has neither antibody, and blood group O has both. A person whose blood contains either (or both) of the anti-A or anti-B antibodies cannot receive a transfusion of blood containing the corresponding incompatible antigen(s). If a person receives a transfusion of blood of an incompatible group, the blood transfusion recipient's antibodies coat the red blood cells of the transfused incompatible group and cause the transfused red blood cells to agglutinate, or stick together. Transfusion reactions and/or hemolysis (the destruction of red blood cells) may result therefrom.
In order to avoid red blood cell agglutination, transfusion reactions and hemolysis, transfusion blood type is cross-matched against the blood type of the transfusion recipient. For example, a blood type A recipient can be safely transfused with type A blood which contains compatible antigens. Because type 0 blood contains no A or B antigens, it can be transfused into any recipient with any blood type, i.e., recipients with blood types A, B, AB or 0. Thus, type O blood is considered "universal", and may be used for all transfusions. Hence, it is desirable for blood banks to maintain large quantities of type O blood. However, there is a paucity of blood type O donors. Therefore, it is useful to convert types A, B and AB blood to type O blood in order to maintain large quantities of universal blood products.
In an attempt to increase the supply of type O blood, methods have been developed for converting certain type A, B and AB blood to type O blood. For example, U.S. Patent No. 4,609,627 entitled "Enzymatic Conversion of Certain Sub-Type A and AB Erythrocytes" ("the '627 Patent"), which is incorporated herein by reference, is directed to a process for converting Aint and A2 (including A2B erythrocytes) to erythrocytes of the H antigen type, as well as to compositions of type B erythrocytes which lack A antigens, which compositions, prior to treatment, contained both A and B antigens on the surface of said erythrocytes. The process for converting Aint and A2 erythrocytes to erythrocytes of the H antigen type which is described in the '627 Patent includes the steps of equilibrating certain sub-type A or AB erythrocytes, contacting the equilibrated erythrocytes with purified chicken liver α-N-acetylgalactosaminidase enzyme for a period sufficient to convert the A antigen to the H antigen, removing the enzyme from the erythrocytes and re-equilibrating the erythrocytes. As described in the '627 Patent, α-N-acetylgalactosaminidase obtained from an avian liver (specifically, chicken liver) source was found to have superior activity in respect of enzymatic conversion or cleavage of A antigenic sites.
Prior to the present invention, it was necessary to purify the enzyme from an avian liver source, a process which is time consuming and can be expensive. Hence, a need has arisen to develop an enzyme source which is more readily available. In addition, a need has arisen to develop an enzyme useful in blood product conversion which enzyme is cost-efficient.
A simplified purification process is described in a related application, Serial No. 07/964,756, filed October 22, 1992, entitled "Preparation of Enzyme for Conversion of Sub-Type A and AB Erythrocytes". This process, as described in the related application, utilizes chicken liver as a source of enzyme and, therefore, requires a number of purification steps. Despite this simplified process, it is still desirable to provide a more readily available and controlled source of enzyme, that being cloned and expressed enzyme. This would provide an enzyme source which is more consistent and which is readily purified at less cost and expense, with a still further reduced number of purification steps. Additionally, a recombinant, cloned enzyme allows for specific protein sequence modifications, which can be introduced to generate an enzyme with optimized specific activity, substrate specificity and pH range.
α-N-acetylgalactosaminidase enzymes are characterized (and thereby named) by their ability to cleave N-acetylgalactosamine sugar groups. In isolating or identifying these enzymes, their activity is assessed in the laboratory by evaluating cleavage of synthetic substrates which mimic the sugar groups cleaved by the enzymes, with p-nitrophenylglycopyranoside derivatives of the target sugar groups being commonly used. Although very useful in enzyme identification and isolation procedures (the quantitative cleavage of these synthetic substrates can be used to readily distinguish (and thereby identify) enzymes isolated from different sources), these synthetic substrates are simple structurally and small-sized and mimic only a portion of the natural glycoproteins and glycolipid structures which are of primary concern, those being the A antigens on the surface of cells.
A natural glycolipid substrate, originally isolated from sheep erythrocytes, is the Forsmann antigen (globopentaglycosylceramide). The Forsmann antigen substrate appropriately mimics the natural A antigen glycolipid structures and is therefore utilized to predict the activity of α-N-acetylgalactosaminidase enzymes against the A antigen substrate. Isolated Forsmann antigen glycolipids have been shown to inhibit hemolysis of sheep red cells by immune rabbit anti-A serum in the presence of serum complement.
α-N-acetylgalactosaminindase enzyme has been isolated from a number of sources besides chicken liver (described above), including bacteria, mollusks, earthworms, and human liver. The human α-N-acetylgalactosaminidase enzyme has been purified, sequenced, cloned and expressed. For example, in "Human α-N-Acetylgalactosaminidase - Molecular Cloning, Nucleotide Sequence and Expression of a Full-length cDNA", by Wang et al., in The Journal of Biological Chemistry, Vol. 265, No. 35, pages 21859-21866 (December 15, 1990), the cDNA encoding human α-N-acetylgalactosaminidase was sequenced. In addition, in "Molecular Cloning of a Full-Length cDNA for Human α-N-Acetylgalactosaminidase (α-Galactosidase B)", by Tsuji et al., in Biochemical And Biophysical Research Communications, Vol. 163, No. 3, pages 1498-1504 (September 29, 1989), the cDNA encoding human α-N-acetylgalactosaminidase was sequenced. Both the nucleotide sequence and the amino acid sequence of human α-N-acetylgalactosaminidase is published therein. Further, PCT Application No. WO 92/07936 discloses the cloning and expression of the cDNA which encodes human α-N-acetylgalactosaminidase.
Although human α-N-acetylgalactosaminidase has been purified, sequenced, cloned and expressed, it is not appropriate for use in removing A antigens from the surface of cells in blood products. In determining whether an enzyme is appropriate for use in removing A antigens from the surface of cells, one must consider the following enzyme characteristics, particularly with respect to the Forsmann antigen substrate: substrate specificity, specific activity or velocity of the substrate cleavage reaction, and pH optimum. Substrate specificity is measured in the Km value, which measures the binding constant or affinity of an enzyme for a particular substrate. The lower a Km value, the more tightly an enzyme binds its substrate. The velocity of an enzyme cleavage reaction is measured in the Vmax, the reaction rate at a saturating concentration of substrate. A higher Vmax indicates a faster cleavage rate. The ratio of these two parameters, Vmax/Km, is a measure of the overall efficiency of an enzyme in reacting with (cleaving) a given substrate. A higher Vmax/Km indicates greater enzyme efficiency. For successful and clinically applicable removal of A antigens from the surface of cells, the enzyme must be sufficiently active at or above a pH at which the cells being treated can be maintained. The procedure described in the '627 patent calls for treatment of cells at or above a pH of 5.6. Therefore, the pH optimum of an appropriate enzyme must still provide reasonable enzyme activity at this pH. These specific characteristics (Vmax/Km, Vmax, Km and pH optimum) are reported for the human α-N-acetylgalactosaminidase enzyme in "Studies on Human Liver α-galactosidases", by Dean et al. in The Journal of Biological Chemistry, Vol. 254, No. 20, pages 10001-10005 (1979).
The Vmax/Km value for the Forsmann antigen of human α-N-acetylgalactosaminidase is 0.46, as compared to a Vmax/Km value of 5.0 for the chicken liver enzyme, indicating an approximately ten-fold difference in efficiency. The Km is lower and the Vmax is higher for the chicken liver enzyme, compared to the human enzyme. Further, human α-N-acetylgalactosaminidase has a pH optimum for the Forsmann antigen of 3.9, compared to 4.7 for chicken liver α-N-acetylgalactosaminidaεe. By all of these enzyme characteristics, human α-N-acetylgalactosaminidase enzyme is not suitable for removal of A antigens, particularly when compared to the chicken liver enzyme.
As a result, a need still existed to develop an enzyme which is capable of removing A antigens from the surface of cells in blood products, wherein said enzyme is readily available and cost-efficient.
It is therefore an object of this invention to provide a recombinant enzyme for use in the removal of A antigens from the surface of cells in blood products.
It is another object of this invention to provide a recombinant enzyme for use in the removal of A antigens from the surface of cells in blood products wherein said enzyme is readily available and may be manufactured on a cost-efficierit basis.
It is a further object of this invention to provide methods of cloning and expressing a recombinant enzyme useful in the removal of A antigens from the surface of cells in blood products.
It is yet another object of this invention to provide a method of removing A antigens from the surface of cells in blood products using a recombinant enzyme. BRIEF DESCRIPTION OF THE DRAWINGS
The above brief description, as well as further objects and features of the present invention, will be more fully understood by reference to the following detailed description of the presently preferred, albeit illustrative, embodiment of the present invention when taken in conjunction with the accompanying drawing wherein:
Figure 1 represents a diagram of the strategy used to clone and sequence the chicken liver α-N-acetylgalactosaminidase cDNA;
Figure 2 represents the nucleic acid sequence and the deduced amino acid sequence of the chicken liver α-N-acetylgalactosaminidase cDNA clone;
Figure 3 represents the expression of chicken liver α-N-acetylgalactosaminidase in bacteria and rabbit reticulocyte lysate as shown by Western blot; Figure 4 represents a homology comparison between α-N-acetylgalactosaminidases and α-galactosidases; and
Figure 5 represents the expression of chicken liver α-N-acetylgalactosaminidase in yeast as shown by Western blot. SUMMARY OF THE INVENTION
This invention is directed to a recombinant chicken liver α-N-acetylgalactosaminidase enzyme, which enzyme has a molecular weight of about 45 kDa, is immunoreactive with an antibody specific for chicken liver α-N-acetylgalactosaminidase, and also has about 80% amino acid sequence homology with human α-N-acetylgalactosaminidase enzyme. The recombinant chicken liver α-N-acetylgalactosaminidase enzyme of this invention has the amino acid sequence depicted in Figure 2, from amino acid number 1 to amino acid number 406. This invention is further directed to methods of cloning and expressing the recombinant chicken liver α-N-acetylgalactosaminidase enzyme, and to a method of using said enzyme to remove A antigens from the surface of cells in blood products so as to convert said blood products of certain A sub-types to type O, thereby rendering said blood products universal for use in transfusion therapy.
DETAILED DESCRIPTION OF THE INVENTION
This invention is directed to a recombinant enzyme for use in the removal of type A antigens from the surface of cells in blood products, thereby converting certain sub-type A blood products to type 0 blood products and certain sub-type AB blood products to type B blood products. The recombinant chicken liver α-N-acetylgalactosaminidase enzyme of this invention has a molecular weight of about 45 kDa and is immunoreactive with an antibody specific for chicken liver α-N- acetylgalactosaminidase. In addition, the recombinant enzyme of this invention has about 80% amino acid sequence homology with human α-N-acetylgalactosaminidase enzyme. The recombinant chicken liver α-N-acetylgalactosaminidase enzyme of this invention has the following nucleic acid and deduced amino acid sequence:
Figure imgf000015_0001
Figure imgf000016_0001
Figure imgf000017_0001
A DNA vector containing a sequence encoding chicken liver α-N-acetylgalactosaminidase was deposited under the
Budapest Treaty with the American Type Culture Collection,
Rockville, Maryland, on March 17, 1993, tested and found viable on March 22, 1993 and catalogued as ATCC No. 75434.
The recombinant chicken liver α-N- acetylgalactosaminidase enzyme of this invention can be cloned and expressed so that it is readily available for use in the removal of A antigens from the surface of cells in blood products. The enzyme of this invention can be cloned and expressed by screening a chicken liver cDNA library to obtain the cDNA sequence which encodes the chicken liver α-N-acetylgalactosaminidase, sequencing the encoding cDNA once it is determined, cloning the encoding cDNA and expressing α-N-acetylgalactosaminidase from the cloned encoding cDNA. This may be performed by obtaining an amplified human α-N-acetylgalactosaminidase fragment capable of use as a screening probe, screening a chicken liver cDNA library, such as the one described hereinabove, using the amplified human α-N-acetylgalactosaminidase fragment as a probe so as to obtain the cDNA sequence of the chicken liver cDNA library which encodes chicken liver α-N-acetylgalactosaminidase, sequencing the encoding DNA, cloning the encoding DNA and expressing chicken liver α-N-acetylgalactosaminidase enzyme from the cloned encoding cDNA. Alternatively, screening can be performed using antibodies which recognize chicken liver α-N-acetylgalactosaminidase.
Methods which are well known to those skilled in the art can be used to construct expression vectors containing the chicken liver α-N-acetylgalactosaminidase coding sequence, with appropriate transcriptional/translational signals for expression of the enzyme in the corresponding expression systems. Appropriate organisms, cell types and expression systems include: cell-free systems such as a rabbit reticulocyte lysate system, prokaryotic bacteria, such as E. coli, eukaryotic cells, such as yeast, insect cells, mammalian cells (including human hepatocytes or Chinese hamster ovary (CHO) cells), plant cells or systems, and animal systems including oocytes and transgenic animals.
The entire chicken liver α-N-acetylgalactosaminidase coding sequence or functional fragments of functional equivalents thereof may be used to construct the above expression vectors for production of functionally active enzyme in the corresponding expression system. Due to the degeneracy of the DNA code, it is anticipated that other DNA sequences which encode substantially the same amino acid sequence may be used. Additionally, changes to the DNA coding sequence which alter the amino acid sequence of the chicken liver α-N-acetylgalactosaminidase enzyme may be introduced which result in the expression of functionally active enzyme. In particular, amino acid substitutions may be introduced which are based on similarity to the replaced amino acids, particularly with regard to the charge, polarity, hydrophobicity, hydrophilicity, and size of the side chains of the amino acids.
Once a recombinant chicken liver α-N-acetylgalactosaminidase enzyme is cloned and expressed, said enzyme can be used to remove A antigens from the surface of cells in blood products. Methods of utilizing chicken liver α-N-acetylgalactosaminidase to remove A antigens from the surface of erythrocytes can be found in U.S. Patent No. 4,609,627 issued September 2, 1986 to Goldstein, entitled "Enzymatic Conversion of Certain Sub-type A and AB Erythrocytes", which is incorporated herein by reference. Sub-type A antigens can be removed from the surface of erythrocytes by contacting the erythrocytes with the recombinant chicken liver α-N-acetylgalactosaminidase enzyme of this invention for a period of time sufficient to remove the A antigens from the surface of the erythrocytes. EXAMPLE
Isolation and Characterization of the Chicken Liver cDNA Clone
Chicken liver α-N-acetylgalactosaminidase was purified to homogeneity. The enzyme was a glycoprotein with a molecular weight of 80 kDa, and was dissociated into two identical subunits at pH 7.5. Its optimal pH for cleavage of the synthetic p-nitrophenyl-α-N-acetylgalactosaminyl- pyranoside substrate was 3.65 and the activity dropped sharply when the pH was raised above 7. The N-terminal sequence obtained from the purified chicken liver α-N-acetylgalactosaminidase showed a strong homology with the corresponding sequence deduced from the human α-N-acetylgalactosaminidase cDNA clone described in Tsuj i et al., and Wang et al.
In order to isolate and characterize the cDNA clone for chicken liver α-N-acetylgalactosaminidase, two oligonucleotides, corresponding to nucleotides 688 to 705 and 1219 to 1236 of the human α-N-acetylgalactosaminidase sequence published by Wang, et al. were synthesized. Using human placental mRNA (Clontech) as a template, the specific cDNA was made from the downstream (C-terminal) oligonucleotide. Next, a DNA fragment corresponding to human α-N-acetylgalactosaminidase residues from 688 to 1236 was amplified from the cDNA by the hot-start PCR technique. The PCR reaction mixture was preheated at 95°C for 5 minutes and maintained at 80°C while Taq DNA polymerase (Promega) was added to reduce the possible non-specific annealing at lower temperature. 35 cycles of amplification was then carried out as follows: 94°C for 1 minute, 50°C for 2 minutes and 72°C for 3 minutes. The same conditions for PCR were applied in all of the following experiments. The PCR-amplified fragment was then used as a radioactively-labeled probe in the screening of a chicken liver cDNA library (Stratagene) based on homology hybridization. The filters containing the library were hybridized with the probe overnight at 42°C in a solution of 50% formamide, 5XSSPE, 5XDenhardt ' s, 0.1% SDS and 0.1 mg/ml salmon sperm DNA. The filters were then washed as follows:
1. 3 X SSC + 0.1% SDS, 20 min. room temperature
2. 2 X SSC + 0.1% SDS, 20 min. room temperature 3. 1 X SSC + 0.1% SDS, 20 min. 56°C
4. 1 X SSC + 0.1% SDS, 20 min. 56°C
The filters were autoradiographed overnight at -70°C.
The positive clones were picked up for the second-round screening following the same procedure. In total, three consecutive screenings were carried out in order to obtain a well-isolated positive clone.
From approximately one million plaques screened, one positive clone was successfully isolated. The sequencing data indicated that the clone consists of a 1.2 kb 3'-untranslated region and a 0.7 kb coding region which is highly homologous to human α-N-acetylgalactosaminidase. In order to obtain the missing coding sequence, the library was rescreened by using the 1.9 kb cDNA clone as a probe. However, no positive clone was identified by this approach. The upstream cDNA sequence was then obtained by applying multiple amplification (the nested PCR technique) of. a second chicken liver cDNA library (Clontech). Figure 1 represents a diagram of the strategy used to clone and sequence the chicken liver α-N-acetylgalactosaminidase cDNA. The cDNA encoding chicken liver α-N-acetylgalactosaminidase contained a 1.2 kb coding region (slashed area) and a 1.2 kb 3' untranslated region. The arrows at the bottom of the diagram indicate the sequencing strategy. CL1, CL2 and CL3 are oligonucleotides used as primers for the nested PCR. CL1 and CL2 are located at position 924-941 nt and 736-753 nt, respectively (see Figure 2). According to the N-terminal sequence of native chicken liver enzyme, the oligonucleotide CL3 [5'-CTGGAGAAC(T)GGA(GC)CTGGCT(CA)CG] was designed taking into account chicken codon usage and "best guess".
In the first-round PCR amplification, the whole cDNA library was used as a template in the presence of one specific primer (CL1) (see Figure 1) and one universal primer derived from the library vector (5'-CTGGTAATGGTAGCGACC) . A small aliquot from the above reaction was directly taken for the second-round amplification with a different set of primers. The primer CL2 had the sequence located upstream of CL1 (Figure 1) and the second primer, CL3, was designed based on the N-terminal amino acid sequence from purified chicken liver α-N-acetylgalactosaminidase (see Figure 1). A 750 bp fragment was sequenced to eliminate any possible PCR artifacts. Since the 750 bp fragment overlapped with the 1.9 kb clone isolated by the library-screening, the two fragments were linked together by PCR to reconstitute the cDNA encoding chicken liver α-N-acetylgalactosaminidase (Figure 1). The DNA sequencing was performed according to standard procedure, and the coding region was sequenced in both orientations.
The Cloned DNA Encodes Chicken
Liver α-N-Acetylgalactosaminidase
The authenticity of the cDNA clone was established by co-linearity of deduced amino acid sequences with N-terminal and CNBr-digested peptide sequences from purified chicken liver α-N-acetylgalactosaminidase. Figure 2 represents the nucleic acid sequence and deduced amino acid sequence of the chicken liver α-N-acetylgalactosaminidase cDNA clone. The underlined regions in Figure 2 match sequences obtained from the N-terminus and CNBr-derived fragments of enzyme purified from chicken liver. The first 3 nucleotides, ATG, were added during subcloning to serve as the translational initiation codon for protein expression. The polyadenylation signal (AATAAA) at positions 2299-2304 nt is double-underlined. The boxed sequence indicates potential sites for N-glycosylation. According to the cDNA, the mature protein of 405 amino acids has a molecular mass of about 45 kDa, consistent with that of the purified enzyme estimated by SDS-PAGE. Due to the cloning approach applied, the sequence at the 5' end of the cDNA corresponded to the N-terminal sequence of the mature enzyme isolated from chicken liver.
In order to express the chicken liver α-N-acetylgalactosaminidase in a rabbit reticulocyte lysate, the sequence from 1 to 1260 nucleotides which contained the coding region for chicken liver α-N-acetylgalactosaminidase was subcloned into the vector PCR-II (Invitrogen) in such an orientation that the T7 promoter was located upstream of the insert. Since the N-terminus of the mature protein started with leucine, a translational initiation codon, ATG, was added during the subcloning construction. The construct was then used as a template in a transcription-translation coupled system, TNT system (Promega), for protein expression according to the procedure recommended by the manufacturer.
In order to produce the recombinant α-N-acetylgalactosaminidase in large quantities in bacteria and purify the enzyme in a single-step fashion, the cDNA was subcloned into the EcoRI site of the pTrcHis vector (Invitrogen) for expression in E. coli. Because of the sequence in the vector, the expressed enzyme contained a polyhistidine-tag in its N-terminus, which permitted one step purification by affinity chromatography from crude cell lysates. Figure 3 represents the expression of chicken liver α-N-acetylgalactosaminidase in bacteria and rabbit reticulocyte lysate as shown by Western blotting. Lane 1 through lane 4 demonstrate the results of expression in a rabbit reticulocyte lysate. The expression was carried out in lysate in the presence of 35S-methiomne with (lane 1) or without (lane 2) the expression plasmid. Next, 5 μl of the reaction sample was loaded to a 12% SDS-PAGE. The gel was dried and autoradiographed for 2 hours and a band of an apparent molecular weight of about 45KDa was visualized with the expression plasmid (lane 1, Figure 3). In order to confirm the authenticity of the expressed protein, a Western blot was performed using a polyclonal antibody raised against α-N-acetylgalactosaminidase purified from chicken liver. Using non-labelled methionine instead, the same expression reaction was performed for a Western blot (Promega) as shown in lanes 3 and 4, with and without the expression plasmid, respectively. As indicated in Figure 3, the antibody specifically recognized a band from the reaction with expression plasmid (lane 3), but not in the control (lane 4). Lane 5 shows the protein expressed in bacteria and recognized by the same antibody on Western blot. Lane 6 shows the α-N-acetylgalactosaminidase purified from chicken liver as a positive control. Molecular weight size marker (m) is indicated on the left. Hence, it was confirmed that the isolated cDNA clone codes for the chicken liver α-N-acetylgalactosaminidase.
Comparison of the Cloned Chicken Liver Sequence with other Enzyme Sequences
The chicken liver α-N-acetylgalactosaminidase sequence was compared with published sequences of other α-N-acetylgalactosaminidases and α-galactosidases which cleave α-galactose sugar groups. Figure 4 shows a homology comparison between various α-N-acetylgalactosaminidases and α-galactosidases. Alignment was carried out using both the computer program PROSIS (Hitachi Software Engineering Corp., Ltd.) and manual arrangement. The amino acid sequences were deduced from cDNAs. Sequences I and II are of α-N-acetylgalactosaminidases from chicken liver and human placenta, respectively. Sequences III, IV, V and VI represent α-galactosidase from human, yeast, Cyamopsis tetragonoloba and Aspergillus niger, respectively. Sequences IV and VI are truncated at the C-terminus, as indicated by **. Identical or conservatively substituted amino acid residues (five out of six or more) among the aligned protein sequences are boxed. The numbers above the sequences indicate the relative position of each peptide sequence.
The deduced amino acid sequence from chicken liver α-N-acetylgalactosaminidase cDNA shows approximately 80% homology with the human α-N-acetylgalactosaminidase as determined by PROSIS. This homology indicates the relatedness of the human and chicken liver enzymes, despite the differences in the specific characteristics of the enzymes, particularly with regard to cleavage of the Forsmann antigen, as has already been described. Also, polyclonal antibodies raised against chicken liver α-N-acetylgalactosaminidase enzyme do not cross react with the human enzyme. The specific amino acids responsible for these differences remain to be elucidated.
Yamachi et al. (1990) reported that a human α-N-acetylgalactosaminidase cDNA with an insertion of 70bp at the position corresponding to number 376 in Figure 4 was not enzymatically active in a transient expression study in COS cells. The data suggests that the open reading frame shift caused by this insertion in the C-terminal portion of the molecule is responsible for the loss of enzymatic activity, indicating that amino acids in the C-terminal region may be essential for α-N-acetylgalactosaminidase enzyme activity.
By sequence similarity searching (BLAST) (Altschul et al. 1990) of available protein databases followed by sequence alignment using the PROSIS computer program and manual arrangement, it was found that α-N-acetylgalactosaminidase is highly homologous to α-galactosidases from human, yeast, cyamopsis tetragonoloba and aspergillus niger (ranging from 55% to 68% at the amino acid level). The extent of the amino acid sequence homology, as shown in Figure 4, suggests that these two functionally specific glycosidases might have evolved from a common ancestral gene. Considering the high degree of similarities and the nature of their substrates it is possible that the two exoglycosidases share a similar catalytic mechanism and the critical amino acid residues involved in both active sites are well conserved. The addition of chicken liver α-N-acetylgalactosaminidase cDNA to the family provides further insight into regions of the molecule which are important for the substrate binding specificity and enzymatic activity. Given the availability of cloned enzymes from a number of sources, the active site and catalytic mechanisms of α-N-acetylgalactosaminidase and α-galactosidase enzymes may now be studied by means of cDNA deletion and site-directed mutagenesis. Expression of Active Chicken Liver α-N-acetylgalactosaminidase in Yeast
The first 48 nucleotides of human α-N-acetylgalactosaminidase cDNA (Wang, et al. 1990) which correspond to the signal peptide sequence, were linked to the cloned chicken liver α-N-acetylgalactosaminidase coding region by PCR. The PCR amplified product was subcloned directly into the vector PCR-II (Invitrogen). Two EcoRl sites flanking the insert were used to subclone the entire α-N-acetylgalactosaminidase cDNA into the yeast expression vector pYES2 (Invitrogen) in such an orientation that the GAL 1 promoter was located upstream of the insert. The GAL 1 promoter provides expression of the inserted cDNA clone under galactose inducing growth conditions in yeast.
The yeast vector constructs were transformed into the yeast strain, INVSCI (Invitrogen) using standard procedures. To confirm the expression of the chicken liver α-N-acetylgalactosaminidase in yeast, the total proteins from cell extract and culture supernatant were prepared and separated by 12% SDS-PAGE and a Western blot performed (by standard conditions) using the polyclonal antibody raised against purified chicken liver α-N-acetylgalactosaminidase. The transformed yeast cells were grown in medium without uracil (Bio 101, Inc.). After 0.2% galactose induction, the cells were centrifuged and protein extracts were prepared using glass bead disruption. The secreted proteins in the culture supernatant were concentrated with a Centricon-30 (Amicon Division, W.R. Grace & Co.). The Western blot results are depicted in Figure 5.
Lanes 1 and 8 of Figure 5 show the α-N-acetylgalactosaminidase purified from chicken liver. Lane 2 through lane 4 are cell extracts from the yeast transformed with three different pYES2 constructs: the vector alone (lane 2), chicken liver α-N-acetylgalactosaminidase cDNA coding region (lane 3), and the coding region plus signal sequence (lane 4). Lane 5 is the culture supernatant from transformed yeast used in Lane 4. Lane 7 shows the molecular weight standard. As shown in Figure 5, while the protein without signal peptide was expressed within yeast cells (lane 3), the protein with a signal peptide sequence was predominantly secreted into the media (lane 5). The larger molecular weight of the secreted protein observed on the Western blot was presumably caused by overglycosylation, as was observed for the expression of guar α-galactosidase in yeast (Fellinger, et al. 1991).
To purify the expressed α-N-acetylgalactosaminidase, concentrated culture supernatant was applied to an affinity column containing aminocaproylgalactosylamine agarose. After washing the column, the bound fraction was eluted with buffer containing 50mM N-acetylgalactosamine. This eluate contains expressed α-N-acetylgalactosaminidase of similar molecular weight to that of the enzyme purified from chicken liver, as indicated in lane 6 in Figure 5.
The expressed enzyme eluted from the column demonstrates activity toward the synthetic substrate p-nitrophenyl-α-N-acetylgalactosaminylpyranoside at pH 3.6. Heavily glycosylated enzyme did not bind to the affinity column and showed no activity against synthetic substrate. All the data taken together demonstrate production, secretion and purification of enzymatically active chicken liver α-N-acetylgalactosaminidase in yeast cells. Although the invention herein has been described with reference to particular embodiments, it is to be understood that these embodiments are merely illustrative of various aspects of the invention. Thus, it is to be understood that numerous modifications may be made in the illustrative embodiments and other arrangements may be devised without departing from the spirit and scope of the invention.
SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLICANT: Alex Zhu
Jack Goldstein
(ii) TITLE OF INVENTION: Recombinant α-N-
Acetylgalactosaminidase
Enzyme and cDNA Encoding
Said Enzyme
(iii) NUMBER OF SEQUENCES: 7 (iv) CORRESPONDENCE ADDRESS :
(A) ADDRESSEE: Amster, Rothstein & Ebenstein
(B) STREET: 90 Park Avenue
(C) CITY: New York
(D) STATE: New York
(E) COUNTRY: U.S.A.
(F) ZIP: 10016
(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: 3.5 inch 1.44 Mb storage diskette
(B) COMPUTER: IBM PC Compatible
(c) OPERATING SYSTEM: MS-DOS
(D) SOFTWARE: Word Processor (ASCII)
(vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER: Not yet assigned
(B) FILING DATE: Not yet assigned
(C) CLASSIFICATION: Not yet assigned
(vii) PRIOR APPLICATION DATA: None
(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Pasqualini, Patricia A.
(B) REGISTRATION NUMBER: 34,894
(C) REFERENCE/DOCKET NUMBER: 63475/12
(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: (212) 697-5995
(B) TELEFAX: (212) 286-0854 or 286-0082
(C) TELEX: TWX 710-581-4766 (2) INFORMATION FOR SEQ ID NO: 1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2319
(B) TYPE: nucleic acid
(C) STRANDEDNESS : double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE:
(A) DESCRIPTION: cDNA to mRNA
(iii) HYPOTHETICAL: no
(iv) ANTI -SENSE : yes
(v) FRAGMENT TYPE:
(vi) ORIGINAL SOURCE:
(A) ORGANISM: chicken liver
(B) STRAIN:
(C) INDIVIDUAL ISOLATE:
(D) DEVELOPMENTAL STAGE:
(E) HAPLOTYPE:
(F) TISSUE TYPE:
(G) CELL TYPE:
(H) CELL LINE:
(I) ORGANELLE:
(vii) IMMEDIATE SOURCE: library
(viii) POSITION IN GENOME: unknown
(A) CHROMOSOME SEGMENT:
(B) MAP POSITION:
(C) UNITS:
(ix) FEATURE:
(A) NAME/KEY: chicken liver α-N- acetylgalactosaminidase
(B) LOCATION:
(C) IDENTIFICATION METHOD:
(D) OTHER INFORMATION:
(x) PUBLICATION INFORMATION:
(A) AUTHORS:
(B) TITLE:
(C) JOURNAL:
(D) VOLUME:
(F) PAGES:
(G) DATE: (H) DOCUMENT NUMBER:
(I) FILING DATE:
(J) PUBLICATION DATE:
(K) RELEVANT RESIDUES:
Figure imgf000035_0001
Figure imgf000036_0001
Figure imgf000037_0001
(3) INFORMATION FOR SEQ ID NO: 2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 406
(B) TYPE: amino acid
(C) STRANDEDNESS : double (D) TOPOLOGY: linear
(ii) MOLECULE TYPE:
(A) DESCRIPTION: cDNA to mRNA
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: yes
(v) FRAGMENT TYPE:
(vi) ORIGINAL SOURCE:
(A) ORGANISM: chicken liver
(B) STRAIN: (C) INDIVIDUAL ISOLATE:
(D) DEVELOPMENTAL STAGE:
(E) HAPLOTYPE:
(F) TISSUE TYPE:
(G) CELL TYPE:
(H) CELL LINE:
( I ) ORGANELLE:
(vii) IMMEDIATE SOURCE: library
(viii) POSITION IN GENOME: unknown
(A) CHROMOSOME SEGMENT:
(B) MAP POSITION:
(C) UNITS:
(ix) FEATURE:
(A) NAME/KEY: chicken liver α-N- acetylgalactosaminidase
(B) LOCATION:
(C) IDENTIFICATION METHOD:
(D) OTHER INFORMATION:
(x) PUBLICATION INFORMATION:
(A) AUTHORS:
(B) TITLE:
(C) JOURNAL:
(D) VOLUME:
(F) PAGES:
(G) DATE:
(H) DOCUMENT NUMBER:
(I) FILING DATE:
(J) PUBLICATION DATE:
(K) RELEVANT RESIDUES:
Figure imgf000038_0001
Figure imgf000039_0001
(4) INFORMATION FOR SEQ ID NO: 3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 411
(B) TYPE: amino acid
(C) STRANDEDNESS: double (D) TOPOLOGY: linear
(ii) MOLECULE TYPE:
(A) DESCRIPTION: cDNA to mRNA (iii) HYPOTHETICAL: no
(iv) ANTI -SENSE : yes
(v) FRAGMENT TYPE:
(vi) ORIGINAL SOURCE:
(A) ORGANISM: human
(B) STRAIN:
(C) INDIVIDUAL ISOLATE:
(D) DEVELOPMENTAL STAGE
(E) HAPLOTYPE:
(F) TISSUE TYPE:
(G) CELL TYPE:
(H) CELL LINE:
(I) ORGANELLE:
(vii) IMMEDIATE SOURCE: library
(viii) POSITION IN GENOME: unknown
(A) CHROMOSOME SEGMENT:
(B) MAP POSITION:
(C) UNITS:
( ix) FEATURE :
(A) NAME/KEY : human α-N- acetylgalactosaminidase
( B ) LOCATION :
( C ) IDENTIFICATION METHOD :
(D ) OTHER INFORMATION :
(x) PUBLICATION INFORMATION:
(A) AUTHORS: Wang et al
(B) TITLE: Human α-N-Acetylgalactosaminidase
Molecular Cloning, Nucleotide Sequence, and Expression of a Full-Length cDNA (C) JOURNAL: Journal of Biological Chemistry
(D) VOLUME: 265
(F) PAGES: 21859-21866
(G) DATE: 1990
(H) DOCUMENT NUMBER:
(I) FILING DATE:
(J) PUBLICATION DATE:
(K) RELEVANT RESIDUES:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:
Figure imgf000040_0001
Figure imgf000041_0001
INFORMATION FOR SEQ ID NO : 4 :
( i ) SEQUENCE CHARACTERISTICS :
(A) LENGTH: 429
(B) TYPE: amino acid
(C) STRANDEDNESS : double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE:
(A) DESCRIPTION: cDNA to mRNA
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: yes
(v) FRAGMENT TYPE:
(vi) ORIGINAL SOURCE:
(A) ORGANISM: human
(B) STRAIN:
(C) INDIVIDUAL ISOLATE:
(D) DEVELOPMENTAL STAGE:
(E) HAPLOTYPE:
(F) TISSUE TYPE:
(G) CELL TYPE:
(H) CELL LINE:
(I) ORGANELLE :
(vii) IMMEDIATE SOURCE: library
(viii) POSITION IN GENOME: unknown
(A) CHROMOSOME SEGMENT:
(B) MAP POSITION:
(C) UNITS:
(ix) FEATURE:
(A) NAME/KEY: human α-galactosidase
(B) LOCATION:
(C) IDENTIFICATION METHOD:
(D) OTHER INFORMATION:
(x) PUBLICATION INFORMATION:
(A) AUTHORS: Calhoun et al
(B) TITLE: Fabry Disease: Isolation of a cDNA
Clone Encoding Human α-Galactosidase A
(C) JOURNAL: Proceedings of the National Academy of Science USA
(D) VOLUME: 82
(F) PAGES: 7364-7368
(G) DATE: 1985 (H) DOCUMENT NUMBER:
(I) FILING DATE:
(J) PUBLICATION DATE:
(K) RELEVANT RESIDUES:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:
Figure imgf000043_0001
Figure imgf000044_0001
(6) INFORMATION FOR SEQ ID NO: 5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 438
(B) TYPE: amino acid
(C) STRANDEDNESS : double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE:
(A) DESCRIPTION: cDNA to mRNA
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: yes
(v) FRAGMENT TYPE:
(vi) ORIGINAL SOURCE:
(A) ORGANISM: yeast Saccharomyces cerevisiae
(B) STRAIN:
(C) INDIVIDUAL ISOLATE:
(D) DEVELOPMENTAL STAGE:
(E) HAPLOTYPE:
(F) TISSUE TYPE:
(G) CELL TYPE:
(H) CELL LINE:
(I) ORGANELLE:
(vii) IMMEDIATE SOURCE: library
(viii) POSITION IN GENOME: unknown
(A) CHROMOSOME SEGMENT:
(B) MAP POSITION:
(C) UNITS:
(ix) FEATURE:
(A) NAME/KEY: yeast α-galactosidase (MEL1)
(B) LOCATION: (C) IDENTIFICATION METHOD :
(D) OTHER INFORMATION :
(x) PUBLICATION INFORMATION:
(A) AUTHORS : Liljestrom
(B) TITLE : The Nucleotide Sequence of the
Yeast MEL1 Gene
(C) JOURNAL: Nucleic Acids Research
(D) VOLUME: 13
(F) PAGES: 7257-7268
(G) DATE: 1985
(H) DOCUMENT NUMBER:
(I) FILING DATE:
(J) PUBLICATION DATE:
(K) RELEVANT RESIDUES:
(Xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:
Figure imgf000045_0001
Figure imgf000046_0001
(7) INFORMATION FOR SEQ ID NO: 6:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 411
(B) TYPE: amino acid
(C) STRANDEDNESS : double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE:
(A) DESCRIPTION: cDNA to mRNA
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: yes
(v) FRAGMENT TYPE:
(vi) ORIGINAL SOURCE:
(A) ORGANISM: guar plant Cyamopsis tetragonoloba
(B) STRAIN:
(C) INDIVIDUAL ISOLATE:
(D) DEVELOPMENTAL STAGE:
(E) HAPLOTYPE:
(F) TISSUE TYPE: (G) CELL TYPE:
(H) CELL LINE:
( I ) ORGANELLE :
(vii) IMMEDIATE SOURCE: library
(viii) POSITION IN GENOME: unknown
(A) CHROMOSOME SEGMENT:
(B) MAP POSITION:
(C) UNITS:
(ix) FEATURE:
(A) NAME/KEY: guar α-galactosidase
(B) LOCATION:
(C) IDENTIFICATION METHOD
(D) OTHER INFORMATION:
(x) PUBLICATION INFORMATION:
(A) AUTHORS: Overbeeke et al
(B) TITLE: Cloning and Nucleotide Sequence of the α-Galactosidase cDNA From
Cyamopsis tetragonoloba (guar)
(C) JOURNAL: Plant Molecular Biology
(D) VOLUME: 13
(F) PAGES: 541-550
(G) DATE: 1989
(H) DOCUMENT NUMBER:
(I) FILING DATE:
(J) PUBLICATION DATE:
(K) RELEVANT RESIDUES:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:
Figure imgf000047_0001
Figure imgf000048_0001
(8) INFORMATION FOR SEQ ID NO: 7:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 447
(B) TYPE: amino acid
(C) STRANDEDNESS : double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE:
(A) DESCRIPTION: cDNA to mRNA
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: yes (v) FRAGMENT TYPE:
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Aspergillis niger
(B) STRAIN:
(C) INDIVIDUAL ISOLATE:
(D) DEVELOPMENTAL STAGE:
(E) HAPLOTYPE:
(F) TISSUE TYPE:
(G) CELL TYPE:
(H) CELL LINE:
(I) ORGANELLE:
(vii) IMMEDIATE SOURCE: library
(viii) POSITION IN GENOME: unknown
(A) CHROMOSOME SEGMENT:
(B) MAP POSITION:
(C) UNITS:
(ix) FEATURE:
(A) NAME/KEY: Aspergillus niger α-galactosidase
(B) LOCATION:
(c) IDENTIFICATION METHOD:
(D) OTHER INFORMATION:
(X) PUBLICATION INFORMATION:
(A) AUTHORS: den Herder et al
(B) TITLE: Cloning and Expression of a Member of the Aspergillus niger Gene Family
Encoding α-Galactosidase
(C) JOURNAL: Molecular and General Genetics
(D) VOLUME: 233
(F) PAGES: 404-410
(G) DATE: 1992
(H) DOCUMENT NUMBER:
(I) FILING DATE:
(J) PUBLICATION DATE:
(K) RELEVANT RESIDUES:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:
Figure imgf000049_0001
Figure imgf000050_0001
Figure imgf000051_0001

Claims

WE CLAIM :
1. A recombinant chicken liver α-N- acetylgalactosaminidase enzyme.
2. A recombinant chicken liver α-N- acetylgalactosaminidase enzyme having a molecular weight of about 45 kDa.
3. A recombinant chicken liver α-N- acetylgalactosaminidase enzyme which is immunoreactive with an antibody specific for chicken liver α-N- acetylgalactosaminidase.
4. A recombinant chicken liver α-N- acetylgalactosaminidase enzyme having about 80% amino acid sequence homology with human α-N-acetylgalactosaminidase enzyme.
5. A recombinant chicken liver α-N- acetylgalactosaminidase enzyme including the amino acid sequence depicted in Figure 2, from amino acid number 1 to amino acid number 406.
6. A recombinant vector containing a nucleotide sequence encoding chicken liver α-N-acetylgalactosaminidase.
7. The recombinant vector of Claim 6 which includes the nucleotide sequence depicted in Figure 2, from nucleotide number 1 to nucleotide number 1218.
8. The DNA vector containing a sequence which encodes chicken liver α-N-acetylgalactosaminidase deposited on March 17, 1993 with the American Type Culture Collection, Rockville. Maryland, and catalogued as ATCC No. 75434.
9. A method of producing chicken liver α-N-acetylgalactosaminidase comprising culturing a cell transformed with a recombinant vector containing a nucleotide sequence encoding chicken liver α-N-acetylgalactosaminidase, and recovering chicken liver α-N-acetylgalactosaminidase from said culture.
10. The method of Claim 9 wherein the recombinant vector includes the nucleotide sequence depicted in Figure 2, from nucleotide number 1 to nucleotide number 1218.
11. The method of Claim 9 which further comprises the step of purifying active chicken liver α-N-acetylgalactosaminidase enzyme from said culture by affinity column.
12. The method of Claim 11 wherein the affinity column is aminocaproylgalactosylamine agarose.
13. A method of removing A antigens from the surface of erythrocytes comprising contacting said erythrocytes with recombinant chicken liver α-N-acetylgalactosaminidase enzyme for a period of time sufficient to remove said A antigens from the surface of said erythrocytes.
14. The method of Claim 13 wherein the recombinant chicken liver α-N-acetylgalactosaminidase enzyme has a molecular weight of about 45 kDa.
15. The method of Claim 13 wherein the recombinant chicken liver α-N-acetylgalactosaminidase enzyme is immunoreactive with an antibody specific for chicken liver α-N-acetylgalactosaminidase.
16. The method of Claim 13 wherein the recombinant chicken liver α-N-acetylgalactosaminidase enzyme has about 80% amino acid sequence homology with human α-N-acetylgalactosaminidase.
17. The method of Claim 13 wherein the recombinant chicken liver α-N-acetylgalactosaminidase enzyme includes the amino acid sequence depicted in Figure 2, from amino acid number 1 to amino acid number 406.
PCT/US1994/003338 1993-03-26 1994-03-28 RECOMBINANT α-N-ACETYLGALACTOSAMINIDASE ENZYME AND cDNA ENCODING SAID ENZYME WO1994023070A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP6522254A JPH08508406A (en) 1993-03-26 1994-03-28 Recombinant α-N-acetylgalactosaminidase enzyme and cDNA encoding the enzyme
AU64175/94A AU688310B2 (en) 1993-03-26 1994-03-28 Recombinant alpha-N-acetylgalactosaminidase enzyme and cDNA encoding said enzyme
EP94911730A EP0694081A4 (en) 1993-03-26 1994-03-28 RECOMBINANT -g(a)-N-ACETYLGALACTOSAMINIDASE ENZYME AND cDNA ENCODING SAID ENZYME
CA002159083A CA2159083C (en) 1993-03-26 1994-03-28 Recombinant .alpha.-n-acetylgalactosaminidase enzyme and cdna encoding said enzyme

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3724893A 1993-03-26 1993-03-26
US08/037,248 1993-03-26

Publications (1)

Publication Number Publication Date
WO1994023070A1 true WO1994023070A1 (en) 1994-10-13

Family

ID=21893290

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/003338 WO1994023070A1 (en) 1993-03-26 1994-03-28 RECOMBINANT α-N-ACETYLGALACTOSAMINIDASE ENZYME AND cDNA ENCODING SAID ENZYME

Country Status (5)

Country Link
EP (1) EP0694081A4 (en)
JP (1) JPH08508406A (en)
AU (1) AU688310B2 (en)
CA (1) CA2159083C (en)
WO (1) WO1994023070A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997014786A1 (en) * 1995-10-18 1997-04-24 New York Blood Center, Inc. RECOMBINANT α-N-ACETYLGALACTOSAMINIDASE ENZYME
WO2000063351A2 (en) * 1999-04-21 2000-10-26 Incyte Genomics, Inc. Carbohydrate-modifying enzymes

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4609627A (en) * 1983-08-01 1986-09-02 New York Blood Center, Inc. Enzymatic conversion of certain sub-type A and AB erythrocytes
WO1992007936A1 (en) * 1990-10-24 1992-05-14 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active alpha-n-acetylgalactosaminidase

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5401650A (en) * 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
WO1994009121A1 (en) * 1992-10-22 1994-04-28 The New York Blood Center, Inc. Preparation of enzyme for conversion of sub-type a and ab erythrocytes
CA2149641A1 (en) * 1992-11-18 1994-05-26 Randy M. Berka Methods for converting a, ab and b blood types to o blood type

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4609627A (en) * 1983-08-01 1986-09-02 New York Blood Center, Inc. Enzymatic conversion of certain sub-type A and AB erythrocytes
WO1992007936A1 (en) * 1990-10-24 1992-05-14 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active alpha-n-acetylgalactosaminidase

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Archives of Biochemistry and Biophysics, Volume 280, No. 1, issued July 1990, F. YAGI et al., "Glycosidases of Erlich Ascites Tumor Cells and Ascitic Fluid-Purification and Substrate Specificity of Alpha-N-Acetylgalactosaminidase and Alpha-Galactosidase: Comparison with CoffeeBean Alpha-Galactosidase", pages *
Biochemical and Biophysical Research Communications, Volume 163, No. 3, issued 29 September 1989, S. TSUJI et al., "Molecular Cloning of a Full Length cDNA for Human Alpha-N-Acetylgalactosaminidase (Alpha-Galactosidase B)", pages 1498-1504, see entire document. *
Biochimica et Biophysica Acta, Volume 1216, No. 2, issued November 1993, M.O. DAVIS et al., "Cloning and Sequence of a Chicken Alpha-N-Acetylgalactosaminidase Gene", pages 296-298, see entire document. *
FASEB Journal, Volume 7, No. 7, issued 20 April 1993, A. ZHU et al., "Molecular Cloning and Characterization of a Chicken Liver Alpha-N-Acetylgalactosaminidase", page A1251, see entire document. *
Gene, Volume 137, No. 2, issued December 1993, A. ZHU et al., "Cloning and Characterization of a cDNA Encoding Chicken Liver Alpha-N-Acetylgalactosaminidase", pages 309-314, see entire document. *
Journal of Biological Chemistry, Volume 265, No. 35, issued 15 December 1990, A.M. WANG et al., "Human Alpha-N-Acetylgalactosaminidase-Molecular Cloning, Nucleotide Sequence, and Expression of a Full-Length cDNA", pages 21859-21866, see entire document. *
See also references of EP0694081A4 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997014786A1 (en) * 1995-10-18 1997-04-24 New York Blood Center, Inc. RECOMBINANT α-N-ACETYLGALACTOSAMINIDASE ENZYME
WO2000063351A2 (en) * 1999-04-21 2000-10-26 Incyte Genomics, Inc. Carbohydrate-modifying enzymes
WO2000063351A3 (en) * 1999-04-21 2001-08-09 Incyte Genomics Inc Carbohydrate-modifying enzymes

Also Published As

Publication number Publication date
CA2159083C (en) 2002-07-02
EP0694081A1 (en) 1996-01-31
CA2159083A1 (en) 1994-10-13
EP0694081A4 (en) 1998-07-15
JPH08508406A (en) 1996-09-10
AU688310B2 (en) 1998-03-12
AU6417594A (en) 1994-10-24

Similar Documents

Publication Publication Date Title
Yamamoto et al. Cloning and expression of a marine bacterial β-galactoside α2, 6-sialyltransferase gene from Photobacterium damsela JT0160
Spik et al. A novel secreted cyclophilin-like protein (SCYLP)
AU2010202494B2 (en) Novel alpha-galactosidases
Engel et al. Murein-metabolizing enzymes from Escherichia coli: existence of a second lytic transglycosylase
US5714376A (en) Heparinase gene from flavobacterium heparinum
KR100454174B1 (en) Genes encoding endoglycoceramides
EP0739983A2 (en) Gene encoding lacto-n-biosidase
US5552302A (en) Methods and compositions for production of human recombinant placental ribonuclease inhibitor
KR100541202B1 (en) Genes encoding endoglycoceramidase activators
US6228631B1 (en) Recombinant α-N-acetylgalactosaminidase enzyme and cDNA encoding said enzyme
EP0517174A2 (en) LFA-3 protein and derivatives
AU688310B2 (en) Recombinant alpha-N-acetylgalactosaminidase enzyme and cDNA encoding said enzyme
AU703180B2 (en) Recombinant alpha-galactosidase enzyme and cDNA encoding said enzyme
WO1996023869A1 (en) RECOMBINANT α-GALACTOSIDASE ENZYME
WO1997014786A1 (en) RECOMBINANT α-N-ACETYLGALACTOSAMINIDASE ENZYME
EP0422217B1 (en) Human recombinant placental ribonuclease inhibitor and method of production
WO1998011246A2 (en) ENDO-β-GALACTOSIDASE
US20030129652A1 (en) Human sperm specific lysozyme-like proteins
Zhu et al. Cloning and characterization of a cDNA encoding chicken liver α-N-acetylgalactosaminidase
US5610063A (en) cDNA for α-N-acetyl-galactosaminidase from Gallus domesticus
Zhou-Chou et al. Expression, purification and characterisation of secreted recombinant glycoprotein PsA in Dictyostelium discoideum
EP2502493B1 (en) Novel alpha-galactosidases
CA2397896A1 (en) Human sperm specific lysozyme-like proteins
JP2004024189A (en) Dna encoding heat-resistant keratanase
JPH05199893A (en) Sheep lfa-3 and tm region-deleted lfa-3 protein

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA CN JP NZ

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1994911730

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2159083

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 1994911730

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1994911730

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1994911730

Country of ref document: EP